Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
603368.SS
STRONG BUYGet insider-trade alertsGuangxi LiuYao Group Co., Ltd · Healthcare · China · $854M · Avg Vol: $8M/d
COMPANY DESCRIPTION
Guangxi LiuYao Group is a leading healthcare distributor in southern China, specializing in pharmaceutical wholesaling, retail pharmacy operations, and medical device distribution. The company commands a dominant market share in the Guangxi region, leveraging an extensive logistics network and deep relationships with local hospitals. It is vertically integrated through its expanding traditional Chinese medicine processing and retail pharmacy chains.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.8B | 3.1B | 3.1B | 3.1B | 3.2% | 3.1B | 3.2B | 3.4B | 5.2% |
| EPS | 0.29 | 0.35 | 0.33 | 0.26 | -2.6% | 0.24 | — | — | — |
| Shares | 362.2M | 362.2M | 399.0M | 397.2M | +9.6% | 397.2M | — | — | — |
| Debt | 626.9M | 651.1M | 619.4M | 640.5M | 0.7% | 656.6M | — | — | — |
| Equity | 879.1M | 974.7M | 1.1B | 1.2B | 9.5% | — | — | — | — |
| Op CF | 74.6M | 87.5M | 123.5M | 158.7M | 28.6% | 160.0M | — | — | — |
| Inv CF | -56.5M | -29.8M | -21.0M | -73.9M | — | — | — | — | — |
| Fin CF | -107.7M | -58.5M | 7.9M | -93.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 603368.SS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 603368.SS | Guangxi LiuYao Group Co., Ltd(you) | $854M | 92 | STRONG BUY |
| 301015.SZ | Qingdao Baheal Medical INC. | $1.5B | 86 | STRONG BUY |
| 000028.SZ | China National Accord Medicines Corporation Ltd. | $1.7B | 96 | STRONG BUY |
| 600056.SS | China Meheco Group Co., Ltd. | $1.9B | 80 | BUY |
| 600511.SS | China National Medicines Corporation Ltd. | $2.9B | 98 | STRONG BUY |
| 0874.HK | Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited | $2.9B | 85 | STRONG BUY |
| 600998.SS | Jointown Pharmaceutical Group Co., Ltd | $3.4B | 80 | BUY |
| 2607.HK | Shanghai Pharmaceuticals Holding Co., Ltd | $5.5B | 97 | STRONG BUY |
| 1099.HK | Sinopharm Group Co. Ltd. | $6.3B | 96 | STRONG BUY |
| 000950.SZ | C.Q. Pharmaceutical Holding Co., Ltd. | $1.3B | 51 | HOLD |
Peer medians: ROE 4.8% · P/E 26.5x · Gross margin 52.5%